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Abstract
Objectives—We sought to describe clinical and laboratory findings for a large cohort of patients
with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP).
Background—The thienopyridine derivatives, ticlopidine and clopidogrel, are the 2 most
common drugs associated with TTP in databases maintained by the U.S. Food and Drug
Administration (FDA).
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Methods—Clinical reports of TTP associated with clopidogrel and ticlopidine were identified
from medical records, published case reports, and FDA case reports (n = 128). Duration of
thienopyridine exposure, clinical and laboratory findings, and survival were recorded.
ADAMTS13 activity (n = 39) and inhibitor (n = 30) were measured for a subset of individuals.
Results—Compared with clopidogrel-associated TTP cases (n = 35), ticlopidine-associated TTP
cases (n = 93) were more likely to have received more than 2 weeks of drug (90% vs. 26%), to be
severely thrombocytopenic (84% vs. 60%), and to have normal renal function (72% vs. 45%) (p <
0.01 for each). Compared with TTP patients with ADAMTS13 activity >15% (n = 13), TTP
patients with severely deficient ADAMTS13 activity (n = 26) were more likely to have received
ticlopidine (92.3% vs. 46.2%, p < 0.003). Among patients who developed TTP >2 weeks after
thienopyridine, therapeutic plasma exchange (TPE) increased likelihood of survival (84% vs. 38%,
p < 0.05). Among patients who developed TTP within 2 weeks of starting thienopyridines,
survival was 77% with TPE and 78% without.
Conclusions—Thrombotic thrombocytopenic purpura is a rare complication of thienopyridine
treatment. This drug toxicity appears to occur by 2 different mechanistic pathways, characterized
primarily by time of onset before versus after 2 weeks of thienopyridine administration. If TTP
occurs after 2 weeks of ticlopidine or clopidogrel therapy, therapeutic plasma exchange must be
promptly instituted to enhance likelihood of survival.
Thrombotic thrombocytopenic purpura (TTP) is a severe, multisystem, thrombotic
microangiopathy characterized by thrombocytopenia, microangiopathic hemolytic anemia,
renal dysfunction, neurologic abnormalities, and fever (1). About one-fifth of TTP cases are
associated with pharmaceuticals (2). The thienopyridine derivatives ticlopidine and
clopidogrel are the 2 most commonly reported to the U.S. Food and Drug Administration
(3–5) In 1998, we reported 60 cases of ticlopidine-associated TTP, identifying high survival
rates after therapeutic plasma exchange (TPE) (4,6). Clopidogrel, a newer thienopyridine
derivative, differs in structure from ticlopidine by one methoxycarbonyl group (7). It is now
the second most commonly prescribed drug in the U.S. In 2004, we described 39 patients
with TTP associated with clopidogrel use, highlighting frequent onset within 2 weeks of
drug initiation and high mortality rates despite TPE (5). The manufacturer reported an
incidence of one TTP case per 100,000 clopidogrel treated patients (8).
Marked advances in understanding of TTP pathophysiology have occurred recently. One
area relates to proteolytic processing of plasma von Willebrand factor (VWF) and
characterization of VWF-cleaving protease (VWF) and its inhibitor, an immunoglobulin
(Ig)G autoantibody (9,10). In 2001, VWF-cleaving protease was identified as a metallo-
protease ADAMTS13, belonging to the ADAMTS (a disintegrin-like and metalloprotease
with thrombospondin type 1 motif) family (11). Among idiopathic TTP patients, many have
ADAMTS13 deficiency caused by an inhibitory IgG autoantibody. ADAMTS13 activity has
been measured for seven patients with ticlopidine-associated TTP, and ADAMTS13
deficiency and autoantibodies to ADAMTS13 were identified in all seven patients (12).
Herein, we evaluated clinical, laboratory, and basic science findings for patients with
thienopyridine-associated TTP, representing the largest cohort of individuals with this rare
syndrome reported to date. Our aim is to identify clinically important differences in
presentation and outcome for patients with TTP associated with shorter- versus longer-term
administration of ticlopidine and clopidogrel.
Methods
Investigators with the RADAR (Research on Adverse Drug Events and Reports) project
identified cases of ticlopidine- and clopidogrel-associated TTP with the use of pharmaco-
vigilance methods that have been described previously (3–5,13,14). Thienopyridine-
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associated TTP cases were identified from 4 sources: 1) voluntary reports submitted to Med-
Watch, the Food and Drug Administration’s Safety Information and Adverse Event
Reporting System (n = 29); 2) published case series or reports from MEDLINE/PubMED,
using MeSH terms ticlopidine or clopidogrel, thrombotic microangiopathy, and TTP (n =
40) (4,5,15,16); 3) direct queries of hematologists and apheresis directors in 8 large
apheresis centers in geographically dispersed metropolitan areas (Charles Bennett, MD,
PhD, Chicago, Illinois; Joseph Kiss, MD, Pittsburgh, Pennsylvania; Thomas Ortel MD,
PhD, and Nicholas Bandarenko, MD, Raleigh-Durham, North Carolina; Josh Levy, MD, and
Nurit Begani, RN, Los Angeles, California; William Bell, MD, PHD, Baltimore, Maryland;
Leo J McCarthy, MD, Indianapolis, Indiana; Jean Connors, MD, Boston, Massachusetts; and
Joel Moake, MD, Houston, Texas; n = 42); and 4) a national referral laboratory in Japan
(Yoshihiro Fujimura; n = 17). A validated case report form was used to collect data on
sociodemographic characteristics, thienopyridine use, clinical data—platelet count (per
mm3), hemoglobin level (g/dl), serum creatinine (mg/dl), neurologic findings (altered mental
status, seizure, stroke, or coma)—use of TPE, and survival (4,5). Inclusion criteria were
thienopyridine use before the development of thrombocytopenia (platelets <50,000/mm3)
and microangiopathic hemolytic anemia on peripheral blood smear, without the presence of
any other identifiable cause, such as disseminated intravascular coagulation, cancer, or
preeclampsia. Those cases that did not fulfill or report all of the required inclusion criteria
were excluded from analysis.
Assaying of ADAMTS13 activity
Basic laboratory studies were conducted by investigators with the Surveillance
Epidemiology and Risk Factors for TTP Study Group (17). Plasma was assayed for
ADAMTS13 activity with 3 different methods. Seventeen samples from a Japanese national
referral laboratory compared the classic VWF multimer assay measuring the proteolysis of
purified VWF into cleaved VWF fragments by sodium dodecyl sulfate agarose gel to a
novel enzyme-linked immunoassay technique using monoclonal antibodies directed against
the decapeptide of the VWF-A2 domain ending with the C-terminal edge residue Y1605, a
cleaved VWF byproduct, and found 100% concordance in determining severe ADAMTS13
deficiency (18). Five samples were measured by collagen binding assay, based on the
preferential binding of high-molecular-weight forms of VWF to collagen (15,19). The
measurement of ADAMTS13 activity in the remaining 17 plasma samples was performed
by measuring proteolysis of purified VWF into VWF fragments by gel electrophoresis (20).
Previous studies have reported high levels of concordance in identifying persons with severe
ADAMTS13 deficiency using these methods for assaying ADAMTS13 levels (21). The
inhibitory activity of the IgG autoantibody was determined by mixing TTP plasma samples
at various dilutions with normal plasma and measuring the protease activity of the mixture,
as previously reported and described (20).
Statistical analysis
Bivariate analysis of factors associated with administration of ticlopidine versus clopidogrel,
and shorter- versus longer-term thienopyridine administration, were evaluated with a
nonparametric exact methodology called optimal discriminant analysis. Used to analyze
binary attributes, optimal discriminant analysis yields results isomorphic with the Fisher
exact test and, when used to analyze ordinal attributes, optimal discriminant analysis
identifies a threshold value that explicitly maximizes classification accuracy (22). A cut
point of 2 weeks or less was determined a priori to define short-term thienopyridine
administration based on findings reported previously (3–5). For the subset of patients for
whom ADAMTS13 activity levels were measured, optimal discriminant analysis was used
to evaluate clinical and laboratory findings associated with severe ADAMTS13 deficiency,
characterized as activity levels <15% of normal human plasma as in prior studies (23).
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However, our findings were qualitatively similar if a cut point of 5% was used, a threshold
that was used in some studies (23). A multivariate nonlinear model for predicting survival
from TTP was obtained via hierarchically optimal classification tree analysis (21,24).
Finally, survival analysis was conducted with Cox proportional hazards survival analysis,
with log-rank statistics used to test for differences in the survival outcomes, and Kaplan-
Meier analysis for plotting survival curves.
Results
Between 1998 and 2005, 93 ticlopidine- and 35 clopidogrel-associated TTP cases were
identified (Table 1). Patients with ticlopidine- and clopidogrel-associated TTP were similar
in age (mean 64.2 vs. 58.1 years) and gender (male 53.4% vs. 54.3%) but differed
significantly in duration of thienopyridine exposure prior to development of TTP (p ≤ 0.002)
(Fig. 1A). In comparison with patients with clopidogrel-associated TTP, those with
ticlopidine-associated TTP were more likely to have received more than 2 weeks of a
thienopyridine before TTP (90.3% vs. 25.7%, p < 0.0001) and to present with severe
thrombocytopenia (platelet count <20 × 109/l) (83.9% vs. 60.0%, p < 0.005) but less likely
to have renal insufficiency (27.8% vs. 55.2%, p < 0.02) (Table 1).
We evaluated clinical findings, outcomes, and plasma ADAMTS13 activity for 39
thienopyridine-associated TTP patients (Table 1). In comparison with TTP patients with
ADAMTS13 activity >15%, those with severely deficient ADAMTS13 activity were more
likely to have received ticlopidine (92.3% vs. 46.2%, p ≤ 0.003) and to be severely
thrombocytopenic (96.2% vs. 38.5%, p < 0.001) (Table 1) and had a trend toward
developing TTP after longer periods of drug exposure (Fig. 1B). Among 30 patients with
thienopyridine-associated TTP and plasma available for assays of autoantibody to
ADAMTS13, none with normal ADAMTS13 activity had detectable levels of inhibitor,
whereas every patient with severe ADAMTS13 deficiency had IgG autoantibodies that
inhibited ADAMTS13 activity (p < 0.0001). Survival was greater among thienopyridine-
associated TTP patients with deficient ADAMTS13 activity levels who underwent TPE
compared with those who did not (90.9% vs. 50.0%, p < 0.05). Among six ticlopidine-
associated and seven clopidogrel-associated TTP patients whose ADAMTS13 levels were
>15%, 12 underwent TPE, and only 7 (58.3%) survived.
Overall, the mortality rate for patients with thienopyridine-associated TTP was 25.8%.
Univariate associations identified several characteristics significantly associated with an
increased mortality risk for the total sample, including abnormal neurologic status (p <
0.02), serum creatinine >2.5 mg/dl (p < 0.04), and not receiving TPE (p < 0.0006). Among
patients who developed TTP after >2 weeks of thienopyridine exposure, survival was 2.2-
fold greater when treated with TPE (84% vs. 38%, p < 0.05). Among patients who
developed TTP within 2 weeks of starting thienopyridines, survival was 77% with TPE and
78% without. A multivariate classification tree analysis model revealed that among
thienopyridine-associated TTP patients who received TPE, those patients with ADAMTS13
activity levels >15% at the time of diagnosis of TTP were 4-fold more likely to die (41.9%
vs. 9.1%, p < 0.036).
Discussion
Our study identifies distinct clinical, laboratory, and outcome differences between
ticlopidine- and clopidogrel-associated TTP. More than 90% of the ticlopidine-associated
TTP cases develop after more than 2 weeks of thienopyridine use. Among these patients,
severe thrombocytopenia and preserved renal function at diagnosis is common, ADAMTS13
activity levels are frequently <15%, and survival is 86% if TPE is administered versus 46%
Bennett et al. Page 4













if TPE is not used. These findings are similar to those reported previously for idiopathic
TTP cases with severely deficient ADAMTS13 activity levels (16,23,25). In contrast, three-
quarters of the clopidogrel-associated TTP cases develop after 2 weeks or less of
thienopyridine use. These patients are characterized by mild thrombocytopenia and renal
insufficiency at diagnosis, ADAMTS13 activity levels >15%, and survival rates that are
similar with versus without TPE (72.4% and 66.7%), findings that are similar to those
reported previously for TTP cases with ADAMTS13 activity levels >25%. Our findings
suggest 2 mechanistic pathways for thienopyridine-associated TTP, an immunologic
pathway associated with more than 2 weeks of thienopyridine use and a nonimmunologic
pathway associated with 2 weeks or less of thienopyridine use. In interpreting our study,
several factors should be considered.
The results for patients with severe ADAMTS13 deficiency and thienopyridine-associated
TTP reinforce previous observations for patients with ticlopidine-associated TTP. Tsai et al.
(12) reported 7 ticlopidine-associated TTP patients who had severe ADAMTS13 deficiency
and inhibitors to ADAMTS13 at diagnosis, all of whom responded rapidly to TPE. The use
of TPE in these patients may result in removal of ADAMTS13 inhibitors and ultra-large
VWF multimers, replenishment of ADAMTS13 and VWF, and reduction of cytokines that
induce endothelial cell damage and platelet activation (26). Our study also describes cases of
thienopyridine-associated TTP cases who do not have severe ADAMTS13 deficiency and
whose survival was not influenced by TPE. Preservation of ADAMTS13 activity has been
described in patients with post-transplantation thrombotic microangiopathy (27,28) who
frequently present with renal insufficiency, moderate thrombocytopenia, and high mortality
rates despite TPE. Others have described TTP-like findings among persons with factor V
Leiden mutation (29).
Our study has implications for patient safety. First, for the rare individual with a drug-
eluting coronary artery stent who develops TTP after the administration of clopidogrel and
for whom discontinuation of thienopyridine-therapy could be catastrophic, ticlopidine
challenge can be considered. For most patients with clopidogrel-associated TTP, our
findings suggest that the toxicity is unlikely to be immunologic in etiology. Patel et al. (30)
recently described a case report of a patient with a history of clopidogrel-associated TTP
who successfully received ticlopidine therapy following implantation of a drug eluting
coronary artery stent. Two years had elapsed between the development of clopidogrel-
associated TTP and ticlopidine initiation. Second, the RADAR program has developed new
approaches to drug safety that build on close collaborations with referral centers that have
developed novel assays (13). We identified a large part of our cohort by querying
hematologists or medical directors of TPE centers who were collaborating in a prospective
case-control epidemiologic study or who sent plasma samples for possible TTP cases to a
referral center for measurement of ADAMTS13 activity. Similar collaborations with a
referral center that developed novel assays for detecting antierythropoietin-associated
antibodies facilitated the identification of another drug-associated toxicity, erythropoietin-
associated pure red cell aplasia (31).
Study limitations
The limitations of our study should be identified. First, thienopyridine-associated TTP is
undoubtedly a rare diagnosis, limiting our ability to obtain plasma from large numbers of
patients. Second, although clinical information on most of the cases reported herein have
been reported previously, these studies did not directly compare TTP cases according to
drug (ticlopidine vs. clopidogrel) or the duration of thienopyridine administration (4,5).
Also, previous studies included information on ADAMTS13 activity levels and
ADAMTS13 inhibitors for only 10 patients with thienopyrindine-associated TTP. Third, the
demographic characteristics of the TTP patients in this study differ from those reported in
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case series of TTP patients. In particular, in comparison with thienopyridine-associated TTP
patients, patients in the study of Vesely et al. (24) were younger (mean 35 to 50 vs. 60 to 65
years) and more likely to be female (80% vs. 45%) (16,17,25) and, therefore, there continues
to be uncertainty about causal mechanisms for clopidogrel, primarily because clopidogrel-
associated TTP occurs markedly less often than ticlopidine-associated TTP (32–35).
Conclusions
Thrombotic thrombocytopenic purpura is a rare complication of thienopyridine treatment.
This drug toxicity appears to occur by 2 different mechanistic pathways, characterized
primarily by time of onset of > versus <2 weeks of thienopyridine administration. If TTP
occurs after 2 weeks of ticlopidine or clopidogrel therapy, TPE must be promptly instituted
to enhance the likelihood of survival.
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Figure 1. Duration of Thienopyridine Exposure Prior to TTP Onset
(A) Thienopyridine-associated thrombotic thrombocytopenic purpura (TTP) onset:
ticlopidine versus clopidogrel (p = 0.0016). (B) Thienopyridine-associated TTP onset:
ADAMTS13 deficient versus ADAMTS13 nondeficient (p > 0.05).
Bennett et al. Page 9




































































































































































































































































































































































































































































































































































Bennett et al. Page 11
Table 2





All patients (n= 128)* 81.6 50.0
Ticlopidine (N = 93) * 85.5 45.8
    Ticlopidine Rx ≤ 14 days (n = 9) 100.0 100.0
    Ticlopidine Rx >14 days (n = 84) 84.1* 38.1*
Clopidogrel (N = 35) 72.4 66.7
    Clopidogrel Rx ≤14 days (n = 26) 70.0 66.7
    Clopidogrel Rx >14 days (n = 9) 77.8 —
Thienopyridine Rx ≤ 14 days (n = 35) 76.9 77.8
Thienopyridine Rx >14 days (n = 93) 83.3* 38.1*
*
p < 0.05 (for comparison of survival with TPE vs. without TPE).
Abbreviations as in Table 1.
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